Selected research
Industry Research
Clotting Factors Ⅷ Industry Research Report 2026
Market perspective
The global Clotting Factors Ⅷ market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Clotting Factors Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Clotting Factors Ⅷ is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Clotting Factors Ⅷ is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Clotting Factors Ⅷ include Taibang Biological, Shanghai Laishi, Lvshizi and Hualan Biological, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Clotting Factors Ⅷ market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Clotting Factors Ⅷ Market by Company
Taibang Biological
Shanghai Laishi
Lvshizi
Hualan Biological
Clotting Factors Ⅷ Segment by Type
Injection
Freeze-dried Injection
Clotting Factors Ⅷ Segment by Application
Hemophilia A
Bleeding Diseases
Clotting Factors Ⅷ Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Clotting Factors Ⅷ market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Clotting Factors Ⅷ and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Clotting Factors Ⅷ.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Clotting Factors Ⅷ manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Clotting Factors Ⅷ by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Clotting Factors Ⅷ in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Freeze-dried Injection
Applications
- Hemophilia A
- Bleeding Diseases
Companies covered
- Taibang Biological
- Shanghai Laishi
- Lvshizi
- Hualan Biological
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Clotting Factors Ⅷ Market Size (2021-2032)
- 2.2.2 Global Clotting Factors Ⅷ Sales (2021-2032)
- 2.2.3 Global Clotting Factors Ⅷ Market Average Price (2021-2032)
- 2.3 Clotting Factors Ⅷ by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injection
- 2.3.3 Freeze-dried Injection
- 2.4 Clotting Factors Ⅷ by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hemophilia A
- 2.4.3 Bleeding Diseases
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Clotting Factors Ⅷ Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Clotting Factors Ⅷ Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Clotting Factors Ⅷ Revenue of Manufacturers (2021-2026)
- 3.4 Global Clotting Factors Ⅷ Average Price by Manufacturers (2021-2026)
- 3.5 Global Clotting Factors Ⅷ Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Clotting Factors Ⅷ, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Clotting Factors Ⅷ, Product Type & Application
- 3.8 Global Manufacturers of Clotting Factors Ⅷ, Established Date
- 3.9 Global Clotting Factors Ⅷ Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Taibang Biological
- 4.1.1 Taibang Biological Company Information
- 4.1.2 Taibang Biological Business Overview
- 4.1.3 Taibang Biological Clotting Factors Ⅷ Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Taibang Biological Clotting Factors Ⅷ Product Portfolio
- 4.1.5 Taibang Biological Recent Developments
- 4.2 Shanghai Laishi
- 4.2.1 Shanghai Laishi Company Information
- 4.2.2 Shanghai Laishi Business Overview
- 4.2.3 Shanghai Laishi Clotting Factors Ⅷ Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shanghai Laishi Clotting Factors Ⅷ Product Portfolio
- 4.2.5 Shanghai Laishi Recent Developments
- 4.3 Lvshizi
- 4.3.1 Lvshizi Company Information
- 4.3.2 Lvshizi Business Overview
- 4.3.3 Lvshizi Clotting Factors Ⅷ Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Lvshizi Clotting Factors Ⅷ Product Portfolio
- 4.3.5 Lvshizi Recent Developments
- 4.4 Hualan Biological
- 4.4.1 Hualan Biological Company Information
- 4.4.2 Hualan Biological Business Overview
- 4.4.3 Hualan Biological Clotting Factors Ⅷ Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hualan Biological Clotting Factors Ⅷ Product Portfolio
- 4.4.5 Hualan Biological Recent Developments
5 Global Clotting Factors Ⅷ Market Scenario by Region
- 5.1 Global Clotting Factors Ⅷ Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Clotting Factors Ⅷ Sales by Region: 2021-2032
- 5.2.1 Global Clotting Factors Ⅷ Sales by Region: 2021-2026
- 5.2.2 Global Clotting Factors Ⅷ Sales by Region: 2027-2032
- 5.3 Global Clotting Factors Ⅷ Revenue by Region: 2021-2032
- 5.3.1 Global Clotting Factors Ⅷ Revenue by Region: 2021-2026
- 5.3.2 Global Clotting Factors Ⅷ Revenue by Region: 2027-2032
- 5.4 North America Clotting Factors Ⅷ Market Facts & Figures by Country
- 5.4.1 North America Clotting Factors Ⅷ Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Clotting Factors Ⅷ Sales by Country (2021-2032)
- 5.4.3 North America Clotting Factors Ⅷ Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Clotting Factors Ⅷ Market Facts & Figures by Country
- 5.5.1 Europe Clotting Factors Ⅷ Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Clotting Factors Ⅷ Sales by Country (2021-2032)
- 5.5.3 Europe Clotting Factors Ⅷ Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Clotting Factors Ⅷ Market Facts & Figures by Country
- 5.6.1 Asia Pacific Clotting Factors Ⅷ Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Clotting Factors Ⅷ Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Clotting Factors Ⅷ Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Clotting Factors Ⅷ Market Facts & Figures by Country
- 5.7.1 South America Clotting Factors Ⅷ Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Clotting Factors Ⅷ Sales by Country (2021-2032)
- 5.7.3 South America Clotting Factors Ⅷ Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Clotting Factors Ⅷ Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Clotting Factors Ⅷ Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Clotting Factors Ⅷ Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Clotting Factors Ⅷ Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Clotting Factors Ⅷ Sales by Type (2021-2032)
- 6.1.1 Global Clotting Factors Ⅷ Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Clotting Factors Ⅷ Sales Market Share by Type (2021-2032)
- 6.2 Global Clotting Factors Ⅷ Revenue by Type (2021-2032)
- 6.2.1 Global Clotting Factors Ⅷ Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Clotting Factors Ⅷ Revenue Market Share by Type (2021-2032)
- 6.3 Global Clotting Factors Ⅷ Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Clotting Factors Ⅷ Sales by Application (2021-2032)
- 7.1.1 Global Clotting Factors Ⅷ Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Clotting Factors Ⅷ Sales Market Share by Application (2021-2032)
- 7.2 Global Clotting Factors Ⅷ Revenue by Application (2021-2032)
- 7.2.1 Global Clotting Factors Ⅷ Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Clotting Factors Ⅷ Revenue Market Share by Application (2021-2032)
- 7.3 Global Clotting Factors Ⅷ Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Clotting Factors Ⅷ Value Chain Analysis
- 8.1.1 Clotting Factors Ⅷ Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Clotting Factors Ⅷ Production Mode & Process
- 8.2 Clotting Factors Ⅷ Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Clotting Factors Ⅷ Distributors
- 8.2.3 Clotting Factors Ⅷ Customers
9 Global Clotting Factors Ⅷ Analyzing Market Dynamics
- 9.1 Clotting Factors Ⅷ Industry Trends
- 9.2 Clotting Factors Ⅷ Industry Drivers
- 9.3 Clotting Factors Ⅷ Industry Opportunities and Challenges
- 9.4 Clotting Factors Ⅷ Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst